Association Between Methylenetetrahydrofolate Reductase 677C→T Polymorphism and Response to Transarterial Chemoembolization in Primary Hepatocellular Carcinoma

被引:0
作者
Cui, Lian-hua [1 ]
Song, Yang [1 ]
Liu, Meng [1 ]
Piao, Jin-mei [1 ]
Li, Cheng-cheng [1 ]
Shin, Min-Ho [2 ]
Kim, Hee Nam [3 ]
机构
[1] Qingdao Univ, Dept Publ Hlth, Qingdao 266071, Peoples R China
[2] Chonnam Natl Univ Med Sch, Dept Publ Hlth, Gwangju, South Korea
[3] Chonnam Natl Univ Hwasun Hosp, Genome Res Ctr Hematopoiet Diseases, Hwasun, South Korea
来源
INTERNATIONAL CONFERENCE ON BIOLOGICAL, MEDICAL AND CHEMICAL ENGINEERING (BMCE 2013) | 2013年
基金
中国国家自然科学基金;
关键词
Primary hepatocellular carcinoma; Methylenetetrahydrofolate reductase; Genetic polymorphisms; Transarterial chemoembolization; COLORECTAL-CANCER; 5-FLUOROURACIL; CHEMOTHERAPY; RISK;
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Object: The study aimed to investigate the relationship of methylenetetrahydrofolate reductase 677 -> T polymorphism and transarterial chemoembolization in primary hepatocellular carcinoma. Method: 125 patients with primary hepatocellular carcinoma were treated with transarterial chemoembolization (TACE) alone. However, 63 patients of them underwent TACE using lipiodol mixed with cisplatin(DDP), Pirarubicin(THP) and mitomycin(MMC), and another 62 patients were given cisplatin (DDP), Pirarubicin(THP), and 5 - fluorouracil (5-FU). Clinical response was evaluated after one or two months. MTHFR C677T polymorphisms were determined by Real-time quantitative polymerase chain reaction (Real-time PCR). Results: the overall response rate (CR+PR) was 35.2%. Among the DDP + THP+ MMC and DDP+ THP+ 5-FU chemotherapy program, the response rate was 38.1% and 32.3% respectively, which had no statistically significant difference (p for trend=0.494). According to our results the MTHFRC677T gene polymorphism had no significant influence to the chemosensitivity of the both program. Conclusion: MTHFR C677T polymorphism has no significant roles in transarterial chemoembolization of which common drugs used in primary hepatocellular carcinoma. In addition, there is no significant meaning to detect the genotype of MTHFR C677T when choosing drugs in liver cancer therapy.
引用
收藏
页码:63 / 67
页数:5
相关论文
共 18 条
  • [1] [Anonymous], 1985, CANCER, V56, P918
  • [2] Chen J, 1996, CANCER RES, V56, P4862
  • [3] Folate and carcinogenesis: An integrated scheme
    Choi, SW
    Mason, JB
    [J]. JOURNAL OF NUTRITION, 2000, 130 (02) : 129 - 132
  • [4] Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population
    Cui, Lian-Hua
    Shin, Min-Ho
    Kweon, Sun-Seog
    Kim, Hee Nam
    Song, Hye-Rim
    Piao, Jin-Mei
    Choi, Jin-Su
    Shim, Hyun Jeong
    Hwang, Jun Eul
    Kim, Hyeong-Rok
    Park, Young-Kyu
    Kim, Soo-Hyun
    [J]. BMC CANCER, 2010, 10
  • [5] Duffaud F, 2000, B CANCER, V87, P881, DOI 10.1093/jnci/92.3.205
  • [6] Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity
    Etienne, MC
    Ilc, K
    Formento, JL
    Laurent-Puig, P
    Formento, P
    Cheradame, S
    Fischel, JL
    Milano, G
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (02) : 526 - 534
  • [7] A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE
    FROSST, P
    BLOM, HJ
    MILOS, R
    GOYETTE, P
    SHEPPARD, CA
    MATTHEWS, RG
    BOERS, GJH
    DENHEIJER, M
    KLUIJTMANS, LAJ
    VANDENHEUVEL, LP
    ROZEN, R
    [J]. NATURE GENETICS, 1995, 10 (01) : 111 - 113
  • [8] TREATMENT OPTIONS IN HEPATOCELLULAR CARCINOMA TODAY
    Livraghi, T.
    Makisalo, H.
    Line, P. -D.
    [J]. SCANDINAVIAN JOURNAL OF SURGERY, 2011, 100 (01) : 22 - 29
  • [9] Lu Jian-Wei, 2004, Ai Zheng, V23, P958
  • [10] Masuda H, 1987, Gan To Kagaku Ryoho, V14, P2912